Drugs / STP-001
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07533591 | May 2026 → Apr 2029 expected | Parkinson disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07085195 | Aug → Dec 2025 overdue | Parkinson disease | Ruijin Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STP-001 | “The investigators design and construct a highly efficient therapeutic injection STP-001 (first drug), through the efficient adeno-associated virus capsid (AAV), neuronal...” NCT07085195 ↗1“The investigators design and construct a therapeutic injection agent called STP-001, through an efficient adeno-associated virus capsid (AAV), a neuronal promoter (hSyn), and a...” NCT07533591 ↗ |
| Action | Inhibit | “using chemical genetic inhibition to intervene in the abnormal activity of the subthalamic nucleus” NCT07085195 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “through the efficient adeno-associated virus capsid (AAV)” NCT07085195 ↗ |
| Route | Other | “accurately inject the drug into the bilateral subthalamic nucleus” NCT07085195 ↗ |